The central nervous system market is split into numerous segment including depression, anxiety, schizophrenia, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), migraine and addiction therapies, among others.  
While established treatments are available for each of these therapeutic subcategories, these markets are large and significant unmet medical needs remain.  Treatments under development, both novel and well established, seek to address these opportunities.